Tilt Investment Management Holdings PBC Has $280,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Tilt Investment Management Holdings PBC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 23.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,150 shares of the medical instruments supplier’s stock after selling 343 shares during the period. Tilt Investment Management Holdings PBC’s holdings in Becton, Dickinson and Company were worth $280,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Householder Group Estate & Retirement Specialist LLC bought a new position in Becton, Dickinson and Company during the third quarter worth $25,000. OFI Invest Asset Management bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. Fortitude Family Office LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $35,000. Venturi Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 552.0% in the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 138 shares during the period. Finally, Advisors Asset Management Inc. acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $40,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $0.32 during trading on Thursday, hitting $231.89. The company had a trading volume of 403,671 shares, compared to its average volume of 1,400,148. The firm has a market capitalization of $66.99 billion, a P/E ratio of 55.04, a price-to-earnings-growth ratio of 1.91 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The stock’s 50-day moving average price is $240.34 and its 200 day moving average price is $242.65.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.98 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. Becton, Dickinson and Company’s payout ratio is 90.05%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BDX. Raymond James increased their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays upped their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.